Delta-Fly Pharma, Inc. announced a private placement of unsecured bonds for an aggregate gross proceeds of Ã1,300,842,000 on November 17, 2022. The transaction included participation from Macquarie Group Limited. The transaction has been approved by the board of directors of the company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
737 JPY | -0.41% | +1.10% | -27.39% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
737 JPY | -0.41% | +1.10% | 37.62M | ||
188.2 AUD | -0.88% | -1.29% | 45.84B | ||
1st Jan change | Capi. | |
---|---|---|
-27.39% | 37.62M | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- 4598 Stock
- News Delta-Fly Pharma, Inc.
- Delta-Fly Pharma, Inc. announced that it expects to receive Ñ1.300842 billion in funding from Macquarie Group Limited